Plain-English translation of NCT06129968 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →This trial is testing whether a blood test called ROMA (Risk of Malignancy Algorithm) can detect ovarian cancer earlier and more accurately than the standard tests doctors currently use. ROMA combines two blood markers to identify which women with symptoms need hospital referral. The study will analyze blood samples from thousands of women to see if this medication approach works better in everyday primary care settings.
Ovarian cancer is much more treatable when caught early — survival rates drop dramatically from 90% at stage 1 to just 15% at stage 4. Current blood tests miss half of early cancers and cause unnecessary referrals. Research shows this newer test performs better, but it needs to be proven in real-world primary care clinics before the NHS can adopt it.
You likely qualify if…
You likely don't qualify if…
Your participation is straightforward — when your doctor orders a routine CA125 blood test as part of your normal care, your blood sample will also be tested with the newer ROMA blood test at the lab. You won't need extra visits or procedures; this happens alongside your standard testing. The study will track whether this additional test helps identify ovarian cancer earlier in women like you who visit primary care with concerning symptoms.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United Kingdom